Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide

• Published in: Nucleic acids research Vol. 46; no. 3; pp. 1424 - 1440
• Main Authors: Kim, Sang-Soo, Harford, Joe B, Moghe, Manish, Rait, Antonina, Pirollo, Kathleen F, Chang, Esther H
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 16.02.2018
• Subjects: RNA and RNA-protein complexes
• ISSN: 0305-1048; 1362-4962
• DOI: 10.1093/nar/gkx1221

Abstract Intrinsic therapeutic resistance especially in cancer stem cells (CSCs) together with extensive tumor cell infiltration and restricted permeation of the blood-brain barrier (BBB) by drugs may all contribute to the treatment failure in patients with glioblastoma multiforme (GBM). Accumulating evidence suggests that long non-coding RNA (lncRNA), metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) plays a role in tumor cell infiltration and therapeutic resistance of GBM. Using our tumor-targeted nanocomplex, we have modulated the expression of MALAT1 and investigated its impact on GBM cells. Importantly, our nanocomplex is able to target CSCs that are considered to be the prime culprits in therapeutic resistance and recurrence of GBM. Attenuation of MALAT1 by RNA interference significantly lowered the growth, motility and stemness of GBM cells. In addition, silencing of MALAT1 clearly improved the sensitivity of GBM cells to chemotherapeutic agents including the current first-line therapy of GBM [temozolomide (TMZ)]. In animal models of GBM, tumor involution with a modest but statistically significant survival benefit was achieved with concurrent treatment of TMZ and nanocomplex-mediated silencing of MALAT1. These results suggest that combining standard TMZ treatment with lncRNA-targeting therapies using our nanocomplex could substantially enhance the very poor prognosis for GBM patients.